Early Hemodynamic Safety of Simultaneous Initiation of Finerenone and Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes: The CONFIDENCE Trial - PubMed
6 hours ago
- #CKD and T2D
- #combination therapy
- #hemodynamic safety
- The CONFIDENCE trial assessed the early hemodynamic safety of starting finerenone and empagliflozin simultaneously in patients with chronic kidney disease and type 2 diabetes.
- The trial was funded by Bayer, with design collaboration between academic committee members and Bayer.
- Patients showed a reduction in systolic blood pressure by a mean of 6.9 mm Hg two weeks after treatment initiation.
- There were no reports of hyperkalemia or acute kidney injury requiring intervention during the initial safety phase.
- Simultaneous initiation of finerenone and empagliflozin was well-tolerated and demonstrated an early antihypertensive effect.